Articles About Medtech

This Company Brought Us COVID Vaccines, Now They Can Double Your Money in Less than Three Years

0 | By Michael A. Robinson

The pharmaceuticals industry has made huge strides forward in the last few years. Look at what MRNA has done. It’s allowed us to develop vaccines against the novel coronavirus in a previously unheard-of timeframe of less than one year.

Now a major pharma player has made a new acquisition a new space in order to continue diversifying their business.

Many investors might not think about cannabis when thinking about cutting-edge biotech, but that’s exactly where this Big Pharma industry leader is looking.

That’s why they recently agreed to pay some $6.7 billion for a company with a leading drug candidate that includes the use of cannabinoids.

And since we’re no ordinary investors, we know very well that overlooked opportunities like this one are often where the most impressive profits can be found.

I believe this merger shows exactly how the drug giant I have in mind for you today manages to stay on the leading edge of medical science.

The company also has a track record of successful drug partnerships including one that resulted in the breakthrough Covid vaccine I just mentioned a moment ago, as well as a new treatment pill designed to help revolutionize the fight against the global pandemic.

No wonder the company’s stock has been tripling the overall market’s returns.

Let me show you just how this storied firm stays competitive, and how they can make money for you…

Double Your Money in Three Years with This New Digital Pharmacy

0 | By Michael A. Robinson

When we spoke back on November 9, I told you what I’m calling the “autonomous world” is advancing at warp speed.

From self-driving delivery pods to automated factory lines, we’re seeing technology rollout that basically runs itself.

Today, I want to talk to you about another dimension of this new paradigm, autonomous pharmacies.

These automated systems can have a huge impact on an expensive and deadly medical problem.

Some 40% of all hospital admissions each year in the US alone are caused by adverse drug events, nearly all from legally prescribed drugs.

The med-tech firm I have in mind for you is a leader in a sector ResearchandMarkets says will more than double in the next five years to $35.5 billion.

No wonder this firm’s stock gained some 54% over the past year.

Let me show you why it’s poised to double earnings, with stock price likely to follow, in just under three years…

This Life Saving Tech Could Double Your Money in Two Years

0 | By Michael A. Robinson

Despite a global rise in variants of Covid 19, one of last year’s hottest plays on the pandemic shutdowns is getting absolutely slaughtered this year.

I’m talking about the firm that scorched the market because it was a key enabler of folks working from home with some 300 million video chats a day at the peak.

No wonder shares of Zoom Video Communications Inc. soared a stunning 396% last year.

This year, however, the stock is down nearly 44% compared with the S&P 500’s 25% gain.

By contrast, a stock that was flying under the radar despite having a Covid hook and that I told you about nearly a year ago has gone on a tear, rising some 54% so far this year.

The stock recently hit a record high after reporting earnings that crushed forecasts.

Let me show you why this stock will continue to handily beat the market over the long haul…

This Company Is Clearing the Way for Next-Gen Heart treatments

0 | By Michael A. Robinson

When it comes to keeping healthy, calcium can be both friend and foe.

Like we constantly hear from health officials, our bodies need it to reinforce the structures of our teeth and bones, and it’s a part of keeping our body chemistry working efficiently.

But there’s also a downside to calcium; it can impede the circulatory system, and get in the way of some of the miraculous new high-tech procedures that can offer an alternative to open-heart surgery.

I’ve already found a medical innovator that is solving this problem. Not only do they have an $8 billion market to focus on, but their shares are beating the S&P 500 by 531%, or five times over.

And I’d like to show you why I see it going even further up…

Here’s The Technology Battling America’s Invisible Health Crisis

0 | By Michael A. Robinson

With Covid hospitalizations and deaths dramatically on the rise, it’s easy to overlook another major healthcare crisis confronting America.

And yet, it’s one that could affect as many as 120 million of us and pose profound long-term medical issues.

Ironically, the Covid binge eating of “comfort food” we’ve seen over the last 18 months may add to the new level of concern.

Of course, I’m talking about the nation’s obesity crisis.

There’s a silent health crisis A recent report by the American Obesity Association says 42% of Americans are obese.

No wonder a federal panel recently recommended lowering the age to begin screening for diabetes, which is closely tied to being overweight, down to 35.

To me, the two reports together mean that a life sciences firm with a strong diabetes hook will be in high demand.

With that in mind, I want to reveal a company taking on the challenge of this $72.8 billion sector with a leader that is beating the overall market by nearly fourfold…

This Med Tech Innovator Just Doubled, And It Can Do It Again

0 | By Michael A. Robinson

When we last talked last Friday, I showed you how a software executive founded biotech company Veeva Systems Inc. (VEEV) and turned his expertise in cloud software into a 1,253% gain for investors.

That’s over the last seven years, mind you. Enough to turn $25,000 into $338,250 and up to $1.35 million in the next four years.

Here’s the thing. If you’re a “set-and-forget” investor happy to match the S&P 500, you’ve come to the wrong place.

We’re here to crush the market with the foremost innovative tech leaders

Over the seven years I’m talking about, the S&P 500 gained a very respectable 128%.

Not bad. Unless you compare it to VEEV.

Veeva beat it by a staggering 879%.

This Visionary Tech Leader Can Make You a Lot of Money

0 | By Michael A. Robinson

The trial of Elizabeth Holmes of the failed MedTech startup Theranos began this week. We all know the story, but the biggest takeaway for tech investors is that Holmes founded Theranos at a time when venture capitalists were throwing money at any young tech founder who used the word “disrupt” a lot.

Leadership is crucial in the tech world, but wearing turtlenecks or referring to your enterprise as a “state of consciousness” has little to do with it.

I’ve seen our fair share of Elizabeth Holmes’ and Adam Neumann’s, but I’ve also seen real visionary leaders with powerful ideas and solid management skills that can turn ordinary investors into millionaires- leaders like Peter Gassner.

Had you bought the stock of Gassner’s biotech company at the beginning of Aug. 2014, you would have made a 1,253% return. That’s enough to turn $25,000 into $338,250 in just seven years.

Today, in the first of two parts, I’m going to show you why there are two more doubles ahead for a total of $1.35 million…

A 263% Growth Spurt Is Just the Beginning for This MedTech Trailblazer

0 | By Michael A. Robinson

We recently passed the one-year anniversary of a bold call I made about a MedTech leader that was inspired by a reality show.

On June 20, 2020 this pioneer in aesthetic medicine was still flying under Wall Street’s radar.

And that’s just fine with us. As savvy tech investors we know all too well that by beating the so-called “pros” to the punch, we set ourselves up to really crush the market.

Since then, the S&P 500 has risen 39.8% in a historic run, which is nice and all, but the firm I recommended last June smoked those returns by a stunning 560.8%.

As a major disruptor in the plastic surgery market, this firm’s stock is way ahead of my forecast and has actually gained 263% for a nearly four-fold increase in 13 months.

Even with this much growth, I see plenty of upside ahead.

Let me show you why there’s at least another double in the making…

This Franchise’s Stock Will Double While Riding This Unstoppable Healthcare Trend

0 | By Michael A. Robinson

I can say from personal experience that home health care for seniors and hospice services are a godsend to millions.

And not just because there’s a lot of money up for grabs. More on that in a moment.

Here’s the thing. I recently mentioned that my father passed away after a battle with congestive heart failure.

We were fortunate to be able to find a crackerjack health team to work with him in his Virginia home. In fact, they were with him when he passed away on May 27.

So, I know first-hand that these services can bring big emotional payoffs.

More than just an essential service, home healthcare is also a very lucrative field that continues to grow alongside a national trend.

Analysts say the home health care market to be worth $225 billion by 2024.

Today, I’m going to reveal a leader in this field whose stock could double in less than three years…